New Bronchopulmonary Dysplasia Study Findings Recently Were Published by a Researcher at Xuzhou Medical University (Montelukast Sodium to Prevent and Treat Bronchopulmonary Dysplasia in Very Preterm Infants: A Quasi-Randomized Controlled Trial).

A recent study conducted by researchers at Xuzhou Medical University in China explored the efficacy and safety of montelukast in preventing or treating bronchopulmonary dysplasia (BPD) in preterm infants. BPD is a common chronic lung disease in preterm infants with limited treatment options. The study found that while montelukast did not alleviate the severity of BPD, it did shorten the duration of respiratory support and decrease the pulmonary severity score in very preterm infants. There were no significant adverse drug events associated with montelukast treatment. Further research is needed to fully understand the potential benefits of montelukast in treating BPD. [Extracted from the article]